Healthpeak Properties (DOC) Stock Outlook 2026: The 6% Yield Riding a Lab-Space Bottom

The one thing to settle before buying DOC

The confusion around Healthpeak Properties (NYSE: DOC) is simple to state: is it a stable, high-yield healthcare defensive, or a cyclical recovery play on the lab-space market? My read is that it’s both — and that dual identity is exactly what makes the stock interesting and dangerous at the same time.

Here’s my take up front. DOC pays roughly a 6% yield, but a large slice of the cash flow behind that dividend comes from life-science lab real estate that is only now grinding out a bottom. While medical office and senior housing lay down a steady base, how fast the lab segment recovers will drive total return over the next few years. Defense and recovery live in the same ticker.

Buy DOC as a bond proxy and you’ll be rattled by the lab cycle’s swings. Buy it as a pure lab-recovery bet and you’ll underrate the ballast that medical office provides. This piece pulls those two faces apart so you can decide which one you’re actually buying.

What Healthpeak actually operates

DOC bundles three healthcare property types with very different demand dynamics under one roof. Treat it as one company, but analyze it as three businesses.

Segment	Asset type	Main tenants	Demand driver
Life science / labs	Research campuses in Boston, South SF, San Diego	Biotech, pharma, research institutions	Biotech funding and pipelines; highly cyclical
Medical office (outpatient)	Buildings near hospitals	Health systems, physician groups	Aging demographics, shift to outpatient; steady
Senior housing (CCRC)	Continuing care retirement communities	Older residents, operators	Growth in elderly population; labor-cost sensitive

The key here is low correlation across segments. When labs sag, medical office holds. Senior housing rides a separate demographic wave. There’s natural diversification built into a single REIT.

The 2024 Physicians Realty Trust merger reshaped the picture. Pre-merger Healthpeak (ticker PEAK) leaned lab-heavy; absorbing a medical office specialist meaningfully increased the outpatient share and rebalanced the mix. The company took on Physicians Realty’s DOC ticker. It was a deliberate move to dampen lab volatility with medical office stability.

Why REITs are judged on AFFO, not net income

The most common mistake newer investors make with REITs is applying EPS and P/E straight from the equity playbook. Those numbers are close to meaningless here.

Real estate carries large annual depreciation charges on the income statement, yet a well-maintained building often holds or grows in value. Depreciation is a book expense, not a cash outflow. So the industry adds it back to reach FFO (Funds From Operations), then adjusts for recurring maintenance capex and straight-line rent to get AFFO (Adjusted FFO) — the number that actually reflects distributable cash.

Metric	Concept	What it tells you
FFO	Net income + real estate depreciation ± gains on sales	Baseline cash generation of the property operation
AFFO	FFO − maintenance capex, straight-line adjustments	Real cash available to pay dividends
Same-store NOI	Net operating income growth on assets held throughout	Organic rent growth, stripping out M&A effects
Net Debt/EBITDA	Net debt ÷ EBITDA	Leverage health and rate-risk exposure

Dividend safety isn’t “the yield is 6%.” It’s “what percentage of per-share AFFO goes out as dividend.” A low payout ratio leaves room to grow and reinvest; a ratio near or above 100% is a cut-risk flag. Always frame DOC through that lens.

This cash-flow-quality mindset is a completely different language from analyzing US growth names. A recurring-revenue, deferred-revenue software story like the one behind Teledyne (TDY)‘s industrial-tech mix demands a different toolkit than a REIT, where weighted-average lease term (WALT) and re-leasing spreads carry the analysis.

The lab-space bottom: how much should you trust it?

The heart of the DOC thesis is life-science real estate — and that segment has been on a roller coaster.

During 2020-2022, cheap capital and a flood of venture money pushed developers to overbuild lab space in the marquee clusters: Boston/Cambridge, South San Francisco, San Diego. The trouble was that supply outran real leasing demand. When rates rose and biotech funding froze, vacancy climbed and rents softened.

The bottoming case rests on three legs. First, new lab construction starts have collapsed, so once the current pipeline delivers, new supply dries up for years. Second, excess supply gets absorbed over time, with top-cluster, class-A space filling before older buildings. Third, as rates fall and biotech funding — IPOs, venture, pharma partnerships — recovers, leasing demand comes back.

But be honest about what “bottom” means. It’s “not getting worse,” not “up from here.” There’s no guarantee rents snap back quickly, and the recovery will vary sharply by cluster and building grade. If DOC’s lab assets sit in top clusters with class-A space, they’ll capture the recovery first; weaker locations can stay empty longer. That’s why you read lab occupancy and leasing velocity straight from the quarterly results rather than trusting the narrative.

This recovery arc rhymes with a tech cycle — overheating, correction, supply digestion, reacceleration — much like the boom-bust rhythm of a demand-driven cyclical such as Lyft (LYFT)‘s ride-share economics. The difference: with DOC you get paid roughly 6% to wait out the cycle. Cash flow while you wait is the whole appeal of a REIT recovery bet.

Is a rate cut really good news for DOC?

REITs are textbook rate-sensitive assets, hit through three channels.

Financing costs. REITs buy property with debt and service it with rent. Lower rates cut refinancing costs on maturing debt and lift AFFO; higher-for-longer does the reverse.

Asset values (cap rates). Property value is net operating income divided by a cap rate. Falling rates compress cap rates, so values and NAV rise.

Relative appeal. When Treasury and deposit yields fall, a 6% distribution looks better, and capital rotates toward income assets.

By that logic a rate cut is an obvious positive. The catch: what if the cut arrives with a recession? Senior-housing operating results get squeezed and biotech funding stays cold. So the ideal setup for DOC is a “soft-landing” cut — easing without a growth scare — while a panic cut to fend off recession is far more ambiguous. Read the reason for the cut, not just the direction.

Managing a name that lives and dies on rates takes the same instinct as investing in banks and brokers. If you want to build that rate-cycle intuition, the way a wealth manager’s economics flex with rates in the LPL Financial (LPLA) outlook is a useful companion read, and the SCHD dividend ETF guide 2026 frames how income assets broadly respond when yields move.

Where DOC sits against its peers

Healthcare REITs each have a distinct flavor. DOC’s strengths and weaknesses only sharpen when you line it up next to the field.

REIT	Core segments	Character	Relationship to DOC
DOC (Healthpeak)	Labs + medical office + senior housing	Three-legged, lab-recovery optionality	The subject
WELL (Welltower)	Senior housing (operating/SHOP) heavy	Demographic + operating leverage	Partial overlap in senior housing
VTR (Ventas)	Senior housing + medical office + labs	Most similar diversified peer	Competes across the board
ARE (Alexandria)	Pure life-science labs	Top-cluster lab specialist	Direct lab competitor, pure play

Two things stand out. First, if you want a clean bet on the lab recovery, ARE is more direct — but ARE has no cushion when labs are weak. DOC’s medical office and senior housing act as a breakwater. Second, DOC’s closest analog is Ventas; comparing their segment weights, valuation, and leverage tells you which looks relatively cheaper at any given moment.

The way I frame it: DOC is a diversified healthcare REIT with a lab-recovery option attached. Lower volatility than a pure lab bet, more upside than a pure medical office REIT. Whether that middle ground appeals to you is the whole decision.

The risks, honestly stated

Higher-for-longer rates. If inflation stays sticky and cuts get delayed or reversed, DOC faces a double squeeze from refinancing costs and widening cap rates, plus a relative dividend that looks less compelling. Check the debt maturity schedule and the fixed-versus-floating mix.

A slow lab recovery. Even if the bottom thesis is right, the rebound can lag. If oversupply digests slowly and rents stay flat, lab NOI stalls — and DOC could spend years as a “pays 6%, grows nothing” stock.

Weak biotech funding. The root driver of lab demand is biotech’s cash position. If the IPO window and venture funding refreeze, new leasing and renewals weaken. That’s an exogenous variable DOC can’t control.

Senior-housing operating risk. Operating senior-housing results swing on labor costs and occupancy. Staffing shortages and wage inflation pressure margins.

Tenant concentration and renewal risk. Heavy exposure to a few large tenants, or a short WALT, raises the risk of rent giveback at renewal.

This layered risk profile repeats in one form or another across dividend and cyclical names. An energy producer whose cash flow tracks commodity prices — the setup in the Expand Energy (EXE) natural-gas outlook — shows the same tension between a durable base and a swinging cycle that lives inside DOC itself.

A US investor’s playbook for DOC

Angle 1: Income core, held tax-aware

Treat DOC as a monthly income holding. The wrinkle for US investors: REIT dividends are generally taxed as ordinary income rather than at the qualified-dividend rate, so they can sit in a higher bracket, though a portion may qualify for the 20% Section 199A pass-through deduction. Because of that treatment, DOC often earns its keep inside a tax-advantaged account — an IRA or 401(k) — where the ordinary-income drag disappears.

The point isn’t the yield, it’s durability. Before buying, confirm the AFFO payout ratio isn’t stretched and that the lab recovery gives AFFO a path to grow, which supports future dividend increases. Size it as one sleeve of the portfolio and pair it with a broad dividend ETF to diversify single-REIT risk.

Angle 2: Lab-recovery bet, with the dividend paying you to wait

Approach DOC not as a static yield play but as a bet on the lab cycle turning — while collecting income during the wait. The Achilles’ heel of any recovery bet is timing, and here the 6% distribution offsets the holding cost.

Scale in rather than going all at once. Add on confirmation — lab occupancy and leasing spreads genuinely improving in the quarterlies — rather than on hope. If the recovery lands, you capture capital gains plus dividend growth; if it drags, the payout cushions the downside.

Angle 3: Total-return math, taxes and holding period

For a taxable account, remember the split: the ordinary-income dividend stream versus capital gains on the shares, which follow the usual long-term (held over a year) versus short-term rules. An income-focused hold that rarely trades minimizes short-term gains and keeps the tax drag on the distribution as the main line item to manage. If you’re weighing when and how gains get taxed, the capital gains tax guide 2026 lays out the mechanics before you build the position.

Metrics to watch each quarter

If you own or track DOC, build the habit of reading results in this order.

First: per-share AFFO and guidance. Ahead of headline revenue, look at per-share AFFO growth and the direction of any guidance revision. Raised guidance signals dividend-increase capacity; a cut is a warning.

Second: lab occupancy and leasing spreads. This is the heart of the recovery story. Is occupancy bottoming and turning up? Are new and renewal rents landing above expiring ones (positive spreads)?

Third: segment same-store NOI growth. Read organic rent growth in labs, medical office, and senior housing separately, stripping out acquisition effects. Medical office steadiness contrasts with the direction of lab change.

Fourth: leverage and debt maturities. Net Debt/EBITDA, fixed-versus-floating mix, and how much debt matures over the next few years. That’s your gauge of financial risk in the rate environment.

Read those four together and you can judge — beyond the “6% yield” headline — whether the underlying business is actually getting better or worse.

Further reading

• 👉 SCHD Dividend ETF Guide 2026: building a dividend-growth core
• 👉 Capital Gains Tax Guide 2026: strategy and practical filing
• 👉 LPL Financial (LPLA) Stock Outlook 2026
• 👉 Expand Energy (EXE) Stock Outlook 2026

---

This article is informational and reflects an opinion, not investment advice, and it is not a solicitation to buy or sell any security. Investing carries the risk of loss of principal; make decisions based on your own financial situation and risk tolerance. Any description of a company’s business or prospects is as of the time of writing — always confirm the latest filings and consult a professional before investing.